Oncology (A) fever-range WBH
1. Clinical studies using heckel WBH systems
Hohneck AL, Sadikaj L, Heinemann L, Schroeder M, Riess H, Gerhards A, Burkholder I, Heckel-Reusser S, Gottfried J, Hofheinz RD: Patients with Advanced Pancreatic Cancer Treated with Mistletoe and Hyperthermia in Addition to Palliative Chemotherapy: A Retrospective Single-Center Analysis. Cancers (Basel). 2023 Oct 11;15(20):4929. doi: 10.3390/cancers15204929. OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605673/
Zschaeck S, Weingärtner J, Ghadjar P, Wust P, Mehrhof F, Kalinauskaite G, Ehrhardt VH, Hartmann V, Tinhofer I, Heiland M, Coordes A, Kofla G, Budach V, Stromberger C, Beck M: Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study Oral Oncol. 2021 Feb 21;116:105240. Online ahead of print. https://pubmed.ncbi.nlm.nih.gov/33626457/
Rogasch J, Beck M, Stromberger C, Hofheinz F, Ghadjar P, Wust P, Budach V, Amthauer H, Tinhofer I, Furth C, Walter-Rittel TC, Zschaeck S: PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study F1000Res. 2020 Nov 19;9:1350 OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970429/
Kleef R, Nagy R, Baierl A, Bacher V, Bojar H, McKee DL, Moss R, Thoennissen NH, Szász M, Bakacs T Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution Cancer Immunol Immunother. 2020 OPEN ACCESS: https://link.springer.com/article/10.1007/s00262-020-02751-0
Kobayashi Y, Itoa Y, Ostapenko VV, Sakai M, Matsushita N, Imai K, Shimizu K, Aruga A,Tanigawa K: Fever-range whole-body heat treatment stimulates antigen-specificT-cell responses in humans Immunology Letters 162 (2014) 256–261 https://www.ncbi.nlm.nih.gov/pubmed/25256774
Sulyok I, Fleischmann E, Stift A, Roth G, Lebherz-Eichinger D, Kasper D, Spittler A, Kimberger O: Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery Br J Anaesth. 2012 Nov;109(5):754-61 OPEN ACCESS https://academic.oup.com/bja/article/109/5/754/305182/Effect-of-preoperative-fever-range-whole-body
Bull JM, Scott GL, Strebel FR, Nagle VL, Oliver D, Redwine M, Rowe RW, Ahn CW, Koch SM: Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol. Int J Hyperthermia. 2008 Dec;24(8):649-62 https://www.ncbi.nlm.nih.gov/pubmed/18608594
Kraybill WG, Olenki T, Evans SS, Ostberg JR, O'Leary KA, Gibbs JF, Repasky EA: A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models. Int J Hyperthermia. 2002 May-Jun;18(3):253-66 https://www.ncbi.nlm.nih.gov/pubmed/12028640
2. Clinical case reports using heckel WBH systems
Kleef R, Bacher V, Nagy R, Reisegger P, Bakacs T: Complete Remission of Vocal Cord Cancer Treated With Low-Dose Ipilimumab Plus Nivolumab Combined With Interleukin-2 and Hyperthermia Cureus. 2021 Apr 15;13(4):e14500. doi: 10.7759/cureus.14500. OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123238/
Kleef R, Moss R, Szasz AM, Bohdjalian A, Bojar H, Bakacs T: Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2 Integr Cancer Ther. 2018 Dec; 17(4): 1297–1303. OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247552/
Rich LJ, Winslow TB, Alberico RA, Repasky EA, Seshadri M, Singh AK: Enhanced tumour perfusion following treatment with water-filtered IR-A radiation to the thorax in a patient with head and neck cancer. Int J Hyperthermia. 2016 Aug;32(5):539-42, LETTER TO THE EDITOR https://www.ncbi.nlm.nih.gov/pubmed/27150820
Kleef R, Kekic S, Ludwig N: Successful Treatment of Advanced Ovarian Cancer with Thermochemotherapy and Adjuvant Immune Therapy Case Rep Oncol 2012;5:212–215 OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369243/
3. Pre-clinical studies
Rowe RW, Strebel FR, Proett JM, Deng W, Chan D, He G, Siddik ZH, Bull JMC: Fever-Range Whole-body Thermotherapy Combined With Oxaliplatin: A Curative Regimen in a Preclinical Breast Cancer Model Int J Hyperthermia. 2010; 26(6): 565–576 OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045248/
4. Reviews
Bull JMC: A review of immune therapy in cancer and a question: can thermal therapy increase tumor response? Int J Hyperthermia. 2018 Sep;34(6):840-852. OPEN ACCESS: https://www.tandfonline.com/doi/pdf/10.1080/02656736.2017.1387938?needAccess=true
Yagawa Y, Tanigawa K, Kobayashi Y, Yamamoto M: Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery. J Cancer Metastasis Treat 2017;3:218-30 OPEN ACCESS: http://jcmtjournal.com/article/view/2272
Repasky EA, Evans SS, Dewhirst M: Temperature Matters! And Why it Should Matter to Tumor Immunologists. Cancer Immunol Res. 2013 Oct 1; 1(4) OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904378/
Faghihi Moghadam F, Bakhshandeh M, Sahinbas H: Hyperthermia: A Neoadjuvant Therapeutic Approach in Cancer Treatment CANCERPRESS Vol. 3, No.1, March, 2017 OPEN ACCESS: https://www.semanticscholar.org/paper/Hyperthermia%3A-A-Neoadjuvant-Therapeutic-Approach-in-Moghadam-Bakhshandeh/bddde59d4cf9518d10b83029b7ec29ab895d75e7
5. Books, book chapters
Zschaeck S, Beck M: Whole-Body Hyperthermia in Oncology: Renaissance in the Immunotherapy Era? In: Water-filtered Infrared A (wIRA) Irradiation (Ed.: P. Vaupel), pp. 107-115. Springer Nature Switzerland, Cham. DOI: 10.1007/978-3-030-92880-3_8 OPEN ACCESS https://link.springer.com/content/pdf/10.1007%2F978-3-030-92880-3_8
Tanigawa K, Ito Y, Kobayashi Y: Effects of Fever-Range Hyperthermia on T Cell-Mediated Immunity: Possible Combination of Hyperthermia and T Cell-Based Cancer Immunotherapy in: S. Kokura et al. (eds.), Hyperthermic Oncology from Bench to Bedside, Springer Science+Business Media Singapore 2016 https://link.springer.com/chapter/10.1007/978-981-10-0719-4_31
Rowe-Horwege W: Hyperthermia, Systemic in Enceclopedia of Medical Devices and Instrumentation, Second Edition, 2006 John Wiley & Sons, Inc. https://onlinelibrary.wiley.com/doi/10.1002/0471732877.emd138
6. Congress abstracts:
Kleef R, Nagy R, Bacher V, Bakacs T, Lausch T, McKee D, Moss R, Bojar H, Thoennissen N: Low-dose checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavourable immunological profile (MSI low, PD-L1 under 1%, TMB low) – A single-institution experience from 2015 to 2020 The 7th leading International Cancer Immunotherapy Conference in Europe, 2–4 October 2020, virtual conference, P08.01 J Immunother Cancer 2020;8(Suppl 2):A1–A67 PDF Download
Kleef R, Nagy R, Bohdjalian A, Bacher V, Kekic A, Kekic S, McKee D, Bojar H, Moss R: Complete response of stage IV pancreatic cancer combining dose adapte d checkpoint inhibitors with interleukin 2 (IL 2) and fever range hyperthermia Poster - CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE, 25-28 Sep 2019, Paris PDF Download
Kleef R: Coley remembered – back to the roots. Fevertherapy of cancer in the light of modern immunology. Abstract - Medizinische Woche Baden-Baden 03.10.-03.11.2019 PDF Download
Kleef R, Nagy R, Bohdjalian A, Bacher V, Wychera A, Kekic S, McKee D, Bojar H, Moss R: Complete response of stage IV pancreatic cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia The 6th Leading International Cancer Immunotherapy Conference in Europe / European Journal of Cancer 110 (2019) S22 https://www.ejcancer.com/article/S0959-8049(19)30099-1/fulltext
Wey S: 14 years fever-range whole body hyperthermia in adjuvant recurrence prophylaxis of breast cancer. ESHO 2018 Berlin, P 12 https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 495
Wey S: Secondary and tertiary recurrence prevention with fever range whole-body hyperthermia in (metastatic) malignant melanoma. ESHO 2018 Berlin, P 13 https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 496
Kleef R, Bojar H, Moss R, Stix A, Bohdjalian A, Bacher V, Nagy R, McKee D: Exogenous and endogenous hyperthermia combining lowdose checkpoint inhibitors with interleukin-2 (IL-2) and fever range whole body and local regional hyperthermia in stage IV cancer. ESHO 2018 Berlin, P 35 https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 504
Pinto J, Ferreira A, Ferreira C, Cruz A, Pinto M: Fever-range whole body hyperthermia with concomitant capecitabine in third line therapy for BRCA mutated metastatic breast cancer. ESHO 2018 Berlin, P 38 https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 506
Kleef R, Bohdjalian A, McKee D, Moss RW: Complete response of stage IIIB esophageal cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia. 4th ImmunoTherapy of Cancer Conference, Prague, Czech Republic. 20–22 March 2017, A39 J Immunotherapy Cancer 5, 12 (2017). https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0219-4
Kleef R: Low-dose checkpoint inhibitor therapy with interleukin-2 (IL-2) and fever range hyperthermia in stage IV cancer: a retrospective analysis with single case presentations ESHO 2017 21-23 June Athens, Greece, Abstracts OP-10 ESHO2017 ABSTRACTBOOK , p. 65
Kleef R, Bohdjalian A, McKee D, Moss RW: Complete response of stage IIIB esophageal cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia. Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 1):12 DOI 10.1186/s40425-017-0219-4 https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-017-0219-4 , A39, p.15
Kleef R, Moss RW, Szasz AM, Bohdjalian A, Bakacs T: Near complete remission of pulmonary metastases in triple negative breast cancer (TNBC) using low-dose immune checkpoint (IC) inhibitors with high dose (HD) interleukin-2 (IL-2) and fever range hyperthermia EJC, Vol55, Suppl.1, March 2016; 3rd Immunotherapy of Cancer Conference 21–23 March, 2016, Munich/Germany http://meetinglibrary.asco.org/record/127689/abstract
Oncology (B) extreme WBH
1. Clinical studies using heckel WBH systems
Changlin Zhao , Congqi Dai, Xiaoyin Chen: Whole body hyperthermia combined with intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer Int.J.Hyperthermia, December 2012; 28(8): 735-741 https://www.ncbi.nlm.nih.gov/pubmed/23113543
Douwes F, Bogovic J, Douwes O, Migeod F, Grote C: Whole body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer Int J Clin Oncol. 2004 Apr;9(2):85-91 https://www.ncbi.nlm.nih.gov/pubmed/15108039
Gaworek J, Mayer CT: Systemische Ganzkörperhyperthermie in der Onkologie: Tödliche Hitze für Tumorzellen [Systemic whole body hyperthermia in oncology: fatal heat for tumor cells]. Pflege Z. 2003 Jan;56(1):15-8 [ARTICLE IN GERMAN] http://www.daryan.de/admin/download/file_150.pdf
Reichel M, Scheeren TWL, Douwes O, Konrad RM: Tiefe intravenöse Analgosedierung zur extremen Ganzkörperhyperthermie in Kombination mit Chemotherapie [Deep intravenous analgosedation for extreme whole-body hyperthermia in combination with chemotherapy] Forum Komplementäre Onkologie & Forum Immunologie, 3/2004, 4-8 [ARTICLE IN GERMAN] OPEN ACCESS http://www.rug.nl/research/portal/files/38850130/2004_Tiefe_intravenoese_Analgosedierung_zur_extremen_Ganzkoerperhyperthermie_in_Kombination_mit_Chemotherapie.pdf
|